BioInvent Reports Promising Phase 2a Results for BI-1808 in CTCL

An announcement from BioInvent International AB ( (SE:BINV) ) is now available.

BioInvent International AB has announced promising results from its ongoing Phase 2a study of BI-1808, a monotherapy for Cutaneous T-cell Lymphoma (CTCL). The study has shown encouraging clinical activity with one complete response, three partial responses, and four stable diseases among eight evaluable patients. The treatment demonstrated strong immune activation and was well tolerated, with no severe adverse events reported. These findings, to be presented at the EHA 2025 congress, support further development of BI-1808 as a potential novel treatment option for CTCL, reinforced by its recent Fast Track and Orphan Drug Designation by the FDA.

More about BioInvent International AB

BioInvent International AB is a clinical-stage biotech company specializing in the discovery and development of novel, first-in-class antibodies for cancer immunotherapy. The company is engaged in multiple clinical programs targeting hematological cancers and solid tumors, leveraging its proprietary F.I.R.S.T technology platform to identify promising candidates for its development pipeline and offering licensing and partnering opportunities.

Average Trading Volume: 89,227

Current Market Cap: SEK2.16B

See more insights into BINV stock on TipRanks’ Stock Analysis page.